NCT00147329View on ClinicalTrials.gov

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

July 31, 2006

Conditions
Psoriasis
Interventions
DRUG

MM-093

Trial Locations (2)

75230

Texas Dermatology Research Institute, Dallas

84132

U. of Utah School of Medicine- Department of Dermatology, Salt Lake City

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT00147329 - Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter